相关临床试验
393
136 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
28
7.1%
已完成
125
31.8%
尚未招募
108
27.5%
招募中
109
27.7%
暂停
1
0.3%
终止
15
3.8%
Unknown
2
0.5%
撤回
5
1.3%
暂无批准数据
- Medidata has expanded its six-year partnership with the NHMRC Clinical Trials Centre at the University of Sydney, now supporting 30 concurrent studies through its unified platform. - The collaboration enables streamlined clinical trial operations by consolidating multiple data systems, improving data management capabilities and research efficiency. - The CTC utilizes Medidata solutions particularly for studies that may contribute to regulatory submissions, with emphasis on adaptive and platform trial development. - The partnership demonstrates Medidata's proactive approach to global data privacy and security compliance while supporting complex and evolving trial settings.
- Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors. - The trial demonstrated multiple RECIST responses including a confirmed complete response and partial responses, with systemic immune activation observed even in non-injected lesions across multiple tumor types. - STX-001 was well-tolerated up to 300 µg with dose-dependent increases in plasma IL-12 and IFN-γ, representing the first clinical validation of Strand's programmable mRNA platform technology. - The company plans to advance to Phase 2 monotherapy trials and initiate combination studies with checkpoint inhibitors, while developing STX-003, an intravenous version, for 2026 patient dosing.
